Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulmatrix, Inc. on October 30, 2017. The filing reports the entry into a material definitive agreement regarding the appointment of a new executive officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on the compensation terms of a new executive employment agreement.
Material Changes and Executive Compensation
On October 30, 2017, the Company entered into an Executive Employment Agreement with James Roach, effective November 3, 2017, to serve as Chief Medical Officer. Key terms include:
- Base Salary: $430,000 annually.
- Target Bonus: 40% of base salary starting in 2018; a prorated bonus for 2017 is at the Board's discretion.
- Signing Bonus: 40% of base salary, prorated for the period from January 1, 2017, to November 3, 2017, payable by March 15, 2018.
- Equity Award: Option to purchase 360,000 shares of common stock, vesting over four years (25% on the first anniversary, remaining 75% in equal monthly installments).
- Reimbursements: Up to $15,000 for legal fees and up to $15,000 for repayment of bonuses to a former employer.
Severance and Change of Control Provisions
In the event of a "Qualifying Termination" (termination without cause or resignation for good reason):
- Standard Termination: 9 months of base salary, 75% of the prorated target bonus, full vesting of equity that would have vested in the subsequent 9 months, and up to one year of health benefits.
- Change of Control Termination: If occurring within one year of a change of control, severance increases to 12 months of base salary, the separation bonus increases to 100% of the target, and all outstanding equity awards accelerate immediately. Health benefits continue for up to 12 months or until new employment begins.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 360,000 stock options granted to Dr. Roach.
- Confirm the total cash outlay for the prorated signing bonus and legal fee reimbursements.
- Review the Company's cash position to assess the impact of the new executive compensation package on liquidity.
- Check for any other pending executive appointments or departures that may impact the Company's operational strategy.